Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
| Autor: | Magdy Elkhashab, Giovanni Battista Gaeta, Fehmi Tabak, Patrick Marcellin, Henry Lik-Yuen Chan, Scott Fung, Mani Subramanian, Belinda Jump, Xiaoli Ma, Alain Chan, Robert Flisiak, Maria Buti, Wan-Long Chuang, Florin Alexandru Caruntu, Rajiv Mehta, Aric J. Hui, George V. Papatheodoridis, Jörg Petersen, Sang Hoon Ahn, William Guyer, Won Young Tak, Gerald Crans |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Sustained Virologic Response Tenofovir Physiology Hepatitis b surface antigen Antiviral Agents Gastroenterology Polyethylene Glycols 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Transplant surgery Internal medicine Humans Medicine Hepatitis B Surface Antigens business.industry Correction Interferon-alpha Drug Synergism Middle Aged Hepatology Recombinant Proteins Treatment Outcome 030220 oncology & carcinogenesis Drug Therapy Combination Female 030211 gastroenterology & hepatology Drug Monitoring business Peginterferon alfa-2a medicine.drug |
| Zdroj: | Digestive Diseases and Sciences. 64:285-286 |
| ISSN: | 1573-2568 0163-2116 |
| DOI: | 10.1007/s10620-018-5294-y |
| Popis: | Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72 weeks post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48 weeks compared with either monotherapy. This analysis provides follow-up data at week 120.In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus PEG-IFN for 48 weeks (group A), TDF plus PEG-IFN for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or PEG-IFN for 48 weeks (group D). Efficacy and safety at week 120 were assessed.Rates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C (0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates in group C (P 0.001 for both) or group D (HBsAg loss: P = 0.002; HBsAg seroconversion: P 0.001).The results of this analysis confirm the results from earlier time points which demonstrate the increased rate of HBsAg loss in patients treated with a finite course of PEG-IFN plus TDF compared with the rates in patients receiving either monotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink